QPS Taiwan Awarded GLP-Laboratory Certification by DOH, Taiwan
Newark, DE
QPS, a leading GLP/GCP‑compliant contract research organization providing testing services to support preclinical and clinical research and development, announced today that QPS Taiwan, its Asian operation, has been awarded a Good Laboratory Practice (GLP)‑laboratory certification by the Department of Health (DOH), Executive Yuan, R.O.C. (Taiwan). QPS received this certification due to their exceptional track record and scientific infrastructure, including global Standard Operating Procedures (SOPs), understanding of the regulatory agency of requirement, and planning for the implementation of systems and processes within the Taiwan facility.
“QPS Taiwan has been awarded the first and only GLP-laboratory certification by DOH, Taiwan for bioanalytical services supporting preclinical and clinical research,” stated QPS Taiwan President and CEO, Vincent Yen, M.B.A. “QPS Taiwan shares the same criteria, global SOPs, laboratory procedures, equipment (API 4000 triple quadrupole mass spectrometers, Shimadzu VP-series LCs, Tomtec Quadra), laboratory operations (Rees Monitors, Watson LIMS systems), and systems and processes as QPS U.S.A. We are excited about this certification..."
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
SOUL Trial Shows Oral Semaglutide Significantly Reduces Cardiovascular Risk in Type 2 Diabetes
April 3rd 2025Phase III SOUL trial shows daily oral semaglutide lowers the risk of major adverse cardiovascular events in patients with type 2 diabetes and atherosclerotic cardiovascular disease or chronic kidney disease, with benefits consistent with injectable semaglutide and other GLP-1 receptor agonists.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
